Trial Profile
Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Oxytocin (Primary)
- Indications Autistic disorder; Bipolar disorders; Borderline personality disorders; Personality disorders; Pervasive child development disorders; Schizoaffective disorder; Schizophrenia
- Focus Proof of concept; Therapeutic Use
- 06 Oct 2022 Status changed from suspended to discontinued.
- 13 Oct 2021 Planned End Date changed from 1 Aug 2021 to 1 Jul 2022.
- 13 Oct 2021 Planned primary completion date changed from 1 Aug 2021 to 1 Jul 2022.